Synthszr Charts — die großen AI-Marken im Wettkampf ums Podium
synthszr charts
oracle

Oracle · 2× · zuletzt 21. Aug. 2026

1
Momentum

Oracle Health Clinical AI Agent ist ein KI-gestützter klinischer Assistent, der in die Oracle Health EHR (Millennium-Plattform) integriert ist und Ärzte bei Dokumentation, Kodierung und Chart-Review unterstützt. Im August 2026 wurden neue Funktionen für automatisierte Gebührenkodierung (Professional Fee Coding), klinikerkontrollierte Echtzeit-Diktierfunktion und KI-gestützten Chart-Review in den USA eingeführt. Das System basiert auf einer Multi-Agenten-Architektur mit semantischem Reasoning, die verschiedene KI-Agenten zusammenarbeiten lässt, um klinische Bedeutung zu verstehen und Workflows zu automatisieren, während die Kontrolle beim Kliniker verbleibt. Laut Oracle hat die reine Notiz-Generierungsfunktion bereits über 400.000 Stunden bei US-Gesundheitsorganisationen eingespart.

Momentum-Verlauf
24.08.22.11.

Features

Compliance/ZertifizierungGelistet im NHS England Register für Ambient Voice Technology (AVT)-Anbieter, die NHS-Standards erfüllen
Deployment-ModellCloud-basiert auf Oracle Cloud Infrastructure (OCI), als Standalone-Feature verfügbar, das mit jedem EHR funktionieren kann
EinsatzbereichAmbulante und stationäre Versorgung sowie Notaufnahme, über 30 medizinische Fachrichtungen (u.a. Kardiologie, Nephrologie, Urologie, Verhaltensmedizin)
IntegrationenDirekt integriert in Oracle Health EHR/Millennium-Plattform; Multi-Agenten-System für Order-Erstellung, Coding, Diktat und Chart-Review
PlattformBasiert auf der Oracle Digital Assistant Plattform, integriert in Oracle Health EHR (Millennium), betrieben auf Oracle Cloud Infrastructure (OCI)
PreisNicht öffentlich gelistet; individuelles Angebot je Gesundheitsorganisation
Release-Datum29. Oktober 2024 (2. Generation); neue Coding/Dictation/Chart-Review-Funktionen: 19. August 2026 (USA)

Weitere Produkte in dieser Kategorie: KI im Gesundheitswesen

Belege (2)

Unternehmens-Analyse: Oracle

Stand 17.11.2026
HOLDSynthszr Vote

HOLD is the most data-consistent stance given (1) strong disclosed demand visibility (RPO $664B, +$209B YoY) and raised/affirmed FY27 targets (≥$90B revenue; non-GAAP EPS ~ $8.10), but (2) a still-unresolved cash flow debate due to heavy OCI investment (FY26 FCF negative). (d18rn0p25nwr6d.cloudfront.net) With the current price unspecified and the request to remain strictly data-driven, the prudent approach is to hold while monitoring two objective checkpoints over the next 2–3 quarters: progress converting RPO into recognized cloud revenue and evidence of improving free cash flow/capex efficiency. Valuation screens as mid-teens forward P/E on common aggregators, which supports downside resilience if execution remains solid, but does not by itself justify an aggressive buy without clearer FCF inflection. (finance.yahoo.com)

Zusammenfassung

Oracle Corporation (ORCL) is a diversified enterprise software and cloud services provider with three primary profit engines: (1) Database and middleware software (including high-margin support/maintenance), (2) Cloud Applications (Fusion ERP/HCM, NetSuite, and industry applications), and (3) Cloud Infrastructure (OCI), which includes compute, storage, networking, and increasingly AI/GPU capacity. Oracle’s core competency remains mission-critical data management and enterprise workloads, with a large installed base that supports durable recurring revenue and cross-sell into cloud subscriptions. Market position is strongest in enterprise databases and back-office applications, where switching costs, regulatory/compliance requirements, and deep integration create meaningful customer stickiness. In cloud infrastructure, Oracle is a smaller hyperscaler versus AWS/Azure/Google, but it has differentiated on price-performance for certain workloads, database adjacency, and a rapidly expanding contracted backlog. A key competitive advantage highlighted in recent filings is the scale of contracted future revenue: Oracle reported Remaining Performance Obligations (RPO) of $664B, up $209B year-over-year, indicating substantial multi-year demand visibility (though delivery timing and margin profile depend on capacity build-out and mix). (d18rn0p25nwr6d.cloudfront.net) In the most recent quarter disclosed (Q1 FY27, reported September 10, 2026), Oracle reported sharply higher operating income (GAAP operating income up 57%; non-GAAP operating income up 31%), reflecting operating leverage alongside cloud growth. Management also raised/affirmed a full-year outlook, stating FY27 total revenue is expected to be at least $90B and non-GAAP EPS to be about $8.10. (d18rn0p25nwr6d.cloudfront.net) Recent commentary also emphasized triple-digit growth in cloud infrastructure revenues in that quarter’s release. (investor.oracle.com) Valuation depends on the reference source and timing, but current market data aggregators indicate Oracle trades at a mid-teens forward P/E (e.g., ~13–15x forward P/E) and high-teens trailing P/E, implying the market is pricing in continued earnings expansion but not at “hypergrowth” multiples. (stockanalysis.com) Profitability remains a relative strength versus many cloud peers, though Oracle’s FY26 free cash flow was reported as negative due to heavy infrastructure investment, which is a key near-term constraint and execution focus. (investor.oracle.com) Outlook (short- to medium-term): the next 6–18 months are primarily a capacity-and-delivery story—converting RPO into recognized revenue while managing capex intensity, power/colocation constraints, and margin mix between OCI and applications. If Oracle sustains OCI growth and keeps operating leverage, consensus-style valuation could remain supported; if infrastructure build costs or delivery timelines disappoint, the equity could de-rate despite strong backlog.

Key Takeaways

  1. Oracle’s business model combines sticky, high-margin software support with growing cloud subscriptions across applications and OCI, creating a blended recurring revenue profile.
  2. RPO is exceptionally large ($664B, +$209B YoY), providing unusually high multi-year revenue visibility, but also raising execution risk around delivery capacity and timing. (d18rn0p25nwr6d.cloudfront.net)
  3. Latest reported quarter (Q1 FY27) showed strong operating income growth (GAAP +57%, non-GAAP +31%) and management guided FY27 revenue to at least $90B with non-GAAP EPS about $8.10. (d18rn0p25nwr6d.cloudfront.net)
  4. Oracle’s valuation screens as mid-teens forward P/E and high-teens trailing P/E on common market data sources, suggesting the market is not assigning peak SaaS multiples despite strong cloud momentum. (stockanalysis.com)
  5. FY26 free cash flow was negative due to aggressive OCI investment, making capex discipline, financing conditions, and margin mix central to the equity narrative. (investor.oracle.com)

Action-Ideen

BUY

Accumulate on the view that Oracle’s contracted demand (RPO) and FY27 guidance provide a measurable pathway to earnings growth, while the stock’s forward P/E (mid-teens on major aggregators) implies the market is not fully pricing sustained OCI/application acceleration. Key data points supporting the thesis are: (i) RPO $664B (+$209B YoY), (ii) FY27 revenue guidance ≥$90B and non-GAAP EPS ~ $8.10, and (iii) strong Q1 FY27 operating income growth (GAAP +57%, non-GAAP +31%). Convert USD price exposure to EUR at trade time; thesis does not require a specific entry price but does require monitoring quarterly OCI growth and capex/FCF trajectory.

Horizont: 12 Mon.

HOLD

Maintain exposure if already owned, focusing on confirmation that OCI growth and profitability scale together. The company’s own FY27 guidance (≥$90B revenue; non-GAAP EPS ~ $8.10) provides a near-term benchmark; holding is justified while Oracle continues to meet/raise guidance and demonstrates improving cash generation as major capacity investments mature. This stance is appropriate if valuation remains around mid-teens forward P/E and the investor prefers to wait for clearer evidence of FCF inflection.

Horizont: 6 Mon.

SELL

Reduce exposure if your investment case depends on near-term free cash flow expansion or if valuation rises materially without corresponding improvement in cash generation. Oracle disclosed FY26 free cash flow was negative as it invested heavily in OCI; if subsequent quarters do not show a credible path toward sustainably positive FCF (or if capex continues to rise faster than operating profit), the risk-adjusted return profile can deteriorate even with strong reported backlog. This action is also reasonable for EUR-based investors with low tolerance for USD/EUR volatility.

Horizont: 3 Mon.

Contrarian Insights

  • • Backlog is not the same as near-term earnings quality: Oracle’s RPO is extraordinarily large, but the market may be underestimating how much of that backlog requires sustained capex and time to deliver, which can delay free cash flow normalization even if revenue growth remains strong. (d18rn0p25nwr6d.cloudfront.net)
  • • Valuation may be less demanding than the narrative implies: despite being discussed alongside AI/data-center beneficiaries, common market data sources show Oracle at mid-teens forward P/E, which is closer to mature software/IT services valuation than high-growth SaaS—suggesting upside (or downside) will be driven more by execution versus guidance than by multiple expansion alone. (finance.yahoo.com)

Quellen (8)

Subscribe free. Unsubscribe the second it sucks.

High-signal news across AI, business, UX, and tech. Every morning.